Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges and next steps

Curr Psychiatry Rep. 2012 Oct;14(5):447-9. doi: 10.1007/s11920-012-0295-6.

Authors

Regina Bussing¹, Almut G Winterstein

Affiliation

¹ Department of Psychiatry, College of Medicine, Clinical and Health Psychology, College of Public Health and Health Professions, Room HD-G-20, Human Development Building, Box 100234, University of Florida, Gainesville, FL 32610, USA. rbussing@ufl.edu

PMID: 22684300
DOI: 10.1007/s11920-012-0295-6

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antidepressive Agents / administration & dosage*
Antipsychotic Agents / administration & dosage*
Attention Deficit Disorder with Hyperactivity / drug therapy*
Dopamine Agents / administration & dosage*
Humans
Polypharmacy*

Substances

Antidepressive Agents
Antipsychotic Agents
Dopamine Agents